GLP1R and diabetes mellitus: More recently, systemic or topical administration (eye drops) of GLP-1 and GLP-1R agonists has been reported to prevent electroretinogram abnormalities and neurodegeneration of the retina in rat and mouse models of diabetes [7, 10].